Celularity Inc. (CELU)

Market Cap	41.67M
Revenue (ttm)	54.22M
Net Income (ttm)	-57.89M
Shares Out	23.95M
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,082
Open	1.760
Previous Close	1.760
Day's Range	1.760 - 1.780
52-Week Range	1.001 - 5.220
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	May 8, 2025

About CELU

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating facioscap...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: CELU
• Website: https://www.celularity.com

Financial Performance

In 2024, Celularity's revenue was $54.22 million, an increase of 138.11% compared to the previous year's $22.77 million. Losses were -$57.89 million, -70.51% less than in 2023.